Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Highly Accessed Correction

Correction: Fish oil: what the prescriber needs to know

Leslie G Cleland, Michael J James* and Susanna M Proudman

Author affiliations

Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide, Australia

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2006, 8:402  doi:10.1186/ar1981

The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/8/4/402


Published:1 June 2006

© 2006 BioMed Central Ltd

Correction

It has been brought to our attention that there were a number of typographical errors in one section of our recent article [1] published in December 2005.

All corrections apply to the section entitled, 'Biochemical rationale; Eicosanoids: cyclo-oxygenase pathway'.

The second paragraph should read:

The usual substrate for the COX isozymes is the n6 LC PUFA arachidonic acid (AA; C20:4n-6). Eicosapentaenoic acid (EPA; C20:5n-3), which is present in fish oil, differs from AA only by the presence of its n3 bond (Fig. 1).

The last sentence of the third paragraph should read:

Thus, the net effect of fish oil is to reduce the production of proinflammatory and pro-thrombotic eicosanoids (PGE2 and TXA2, respectively) but not the vascular patency factor prostacyclin (PGI2; Fig. 2).

Finally, the first 20-Carbon fatty acid homologue pictured in Figure 1 (C20:3 n-9) is eicosatrienoic acid, rather than oleic acid.

References

  1. Cleland LG, James MJ, Proudman SM: Fish oil: what the prescriber needs to know.

    Arthritis Research & Therapy 2006, 8:202. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL